Affordable Access

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

Authors
  • Hallberg, Pär
  • Karlsson, Julia
  • Kurland, Lisa
  • Lind, Lars
  • Kahan, Thomas
  • Malmqvist, Karin
  • Ohman, K Peter
  • Nyström, Fredrik
  • Melhus, Håkan
Type
Published Article
Journal
Journal of Hypertension
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Oct 01, 2002
Volume
20
Issue
10
Pages
2089–2093
Identifiers
PMID: 12359989
Source
Medline
License
Unknown

Abstract

The CYP2C9 genotype seems to predict the DBP response to irbesartan, but not to atenolol, in patients with essential hypertension.

Report this publication

Statistics

Seen <100 times